Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529556 | PMC |
| http://dx.doi.org/10.1016/j.mjafi.2013.10.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hazelnut oral immunotherapy desensitizes hazelnut but not other tree nut allergies (Nut CRACKER Study).
J Allergy Clin Immunol Pract
January 2025
Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center; Department of Pediatrics, Faculty of Medicine, Tel Aviv University.
Background: Data on oral immunotherapy (OIT) for hazelnut allergy is limited and its potential to cross-desensitize for other nuts is unknown.
Objective: To study the efficacy and safety of hazelnut OIT in desensitizing hazelnut and additional tree nuts.
Methods: A prospective observational study of 30 hazelnut allergic patients aged ≥4 years who underwent hazelnut OIT.
Anaphylaxis in infancy: An area that needs to be highlighted.
Allergol Immunopathol (Madr)
January 2025
Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece.
Anaphylaxis, the most severe end of the spectrum of allergic reactions, has shown increasing incidence globally over recent years. This hypersensitivity reaction can occur at any age, including infancy. Recent data, although scarce, show that anaphylaxis is increasingly reported in infancy, with food identified as the leading cause of anaphylaxis cases in this age group.
View Article and Find Full Text PDFSafety of 1 mcg/mL as the starting dose in cluster protocol for hymenoptera immunotherapy.
Allergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFAnaphylaxis in pediatric patients: single-center study in a private hospital.
Allergol Immunopathol (Madr)
January 2025
Division of Allergy and Clinical Immunology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
This study aimed to characterize the profile of probable anaphylaxis cases treated at a private pediatric hospital emergency department in São Paulo. It investigated triggering factors, the presence of cofactors, treatments administered, and follow-up for these cases through interviews with the patients' families. A single-center cross-sectional study analyzed medical records of children and adolescents treated between 2016 and 2020.
View Article and Find Full Text PDFRegistries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!